508. IL-33/ST2 Triggering of IL-9-Secreting T Cells: From Proteomics to Therapeutics

As one of the most validated immunotherapies to date, allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative option for high-risk hematological malignancies, particularly acute myeloid leukemia (AML). The immunotherapeutic...

IL-33/ST2 Triggering of IL-9-Secreting T Cells Alters the Balance of Fatal Immunity and Tumor Immunity

Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation

The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation.

Transferred Donor-Derived Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor Can Persist and Provide Anti-Leukemic Activity in AML Patients Post-Transplant

β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Population Distribution of GvL and GvH Minor Histocompatibility Antigens

Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML): Low Incidence of Relapse and Graft Versus Host Disease (GVHD) in Patients (pts) Transplanted without Active Leukemia Using in-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG)

Transferred Donor-Derived WT1-Specific CD8+ T-Cell Clones After Hematopoietic Cell Transplantation Mediate Antileukemic Activity and Can Establish Persistent Responses without Toxicity to Normal Tissues in High-Risk Leukemia Patients

Galectin-3 in host murine models lessens the severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition

Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation

Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT)

Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation